Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553920 | 1.00 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL31451120 | 1.00 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL553740 | 1.00 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL31264458 | 1.00 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL15920349 | 0.88 | CHRM3 (0.48) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL10175100 | 0.85 | MEN1 (0.39) | CHRM1CHRM3SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL24183934 | 0.82 | PDE2A (0.45) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL33532048 | 0.81 | CHRM1 (0.39) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL26647702 | 0.81 | CHRM1 (0.39) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 | |
| SCHEMBL554969 | 0.80 | CHRM1 (0.40) | CHRM1CHRM3CHRM2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | CHRM1 4878/4885CHRM3 4804/4885CHRM2 4830/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CHRM1 4878/4885CHRM3 4804/4885CHRM2 4830/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CHRM1 4878/4885CHRM3 4804/4885CHRM2 4830/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | CHRM1 4885/4885CHRM3 4877/4885CHRM2 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.